[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623732":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":44,"collaborators":19,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":19,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":19,"maxAge":19,"enrollmentInfo":54,"targetDuration":19,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":19,"overallStatus":29,"whyStopped":19,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"Pharmicell Co., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Hearticellgram-AMI","EXPERIMENTAL","Patients with Acute Myocardial Infarction who had administered Hearticellgram-AMI.",[13],"Biological: Hearticellgram-AMI",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"BIOLOGICAL","Patients who had administered Hearticellgram-AMI.",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"DAEUN JUNG","CONTACT","82-2-3496-0134","daeun4100@pharmicell.com",[27],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":19,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"KIMHYUNSOO Clinic","RECRUITING","Seoul","Gangnam","06017","South Korea",{"type":35,"coordinates":36},"Point",[37,38],126.9784,37.566,{"lat":38,"lon":37},[41],{"name":42,"role":23,"phone":43,"phoneExt":19,"email":19},"HYUNSOO KIM","82-2-511-1101",{"type":45,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100623732","long-term-follow-up-study-following-the-approval-of-hearticellgram-ami-administration-100623732",false,"NCT07400458","Long-term Follow-up Study Following the Approval of Hearticellgram-AMI Administration","Long-term Follow-up Study Following the Approval of Hearticellgram-AMI Administration to Evaluate Its Safety in Patients With Acute Myocardial Infarction","Inclusion Criteria:\n\n1. Those who had administered Hearticellgram-AMI\n2. Those who voluntarily agreed in writing to participate in this investigation\n\nExclusion Criteria:\n\n\\-","ALL",{"count":55,"type":56},100,"ESTIMATED","INTERVENTIONAL",[59],"NA","This Long-term follow-up is designed to evaluate the safety of patient with Acute Myocardial Infarction who had administered Hearticellgram-AMI.",[62],"Acute Myocardial Infarction","2026-02-06",{"date":65,"type":66},"2026-02-10","ACTUAL",{"date":68,"type":66},"2022-03-03",{"date":70,"type":56},"2032-09-30",{"name":5,"class":6},1]